electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
Rhea-AI Summary
electroCore (Nasdaq: ECOR) reported preliminary unaudited full-year 2025 results and guidance: record revenue expected at $31.8–$32.0 million, representing ~26% growth versus 2024 ($25.2M). Fourth-quarter 2025 revenue is anticipated at $9.0–$9.2 million, about 30% growth versus Q4 2024. The company ended 2025 with approximately $11.6 million in cash, cash equivalents, and marketable securities, down from ~$13.2 million at September 30, 2025. electroCore described these figures as preliminary unaudited guidance and plans a full operational and financial update on its Q4 and FY2025 earnings call in March 2026.
Positive
- Record full-year revenue of $31.8–$32.0M (~26% YoY)
- Q4 2025 revenue of $9.0–$9.2M (~30% YoY growth)
- Company retains $11.6M in total cash as of Dec 31, 2025
Negative
- Total Cash declined ~12% QoQ from $13.2M to $11.6M
- Revenue guidance is preliminary unaudited, increasing near-term uncertainty
Key Figures
Market Reality Check
Peers on Argus
ECOR gained 5.15% with elevated volume, while peers showed mixed, mostly modest moves (e.g., NMTC +1.28%, MYO +1.67%, RBOT -8.62%). No peers appeared in the momentum scanner, pointing to a stock‑specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Clinical study data | Positive | -0.4% | Peer‑reviewed TAC‑STIM tVNS study showing significant mood and performance benefits. |
| Nov 10 | Conference participation | Positive | +1.3% | Announcement of management participation at a Canaccord Genuity MedTech forum. |
| Nov 05 | Earnings update | Positive | -4.2% | Record Q3 2025 sales, strong growth, higher 2025 revenue guidance, ongoing losses. |
| Oct 23 | Earnings date notice | Neutral | +1.4% | Scheduling of Q3 2025 earnings release and investor webinar details. |
| Oct 03 | Inducement grant | Neutral | +0.0% | Inducement RSU grant to a new VP under Nasdaq Listing Rule 5635(c)(4). |
Recent fundamentally positive and clinical news often saw muted or negative next‑day moves, suggesting a history of cautious reactions to good updates.
Over the last few months, electroCore delivered a series of positive operational updates. Q3 2025 results showed record net sales of $8.7 million, up 33% year‑over‑year, and year‑to‑date net sales of $22.8 million, up 26%, with full‑year 2025 guidance raised to $31.5–$32.5 million. A peer‑reviewed TAC‑STIM™ study in Air Force trainees reported statistically significant performance and mood benefits. Corporate items included RSU inducement grants and conference participation. Today’s preliminary 2025 revenue of about $31.8–$32.0 million aligns with that earlier raised guidance.
Regulatory & Risk Context
An effective S-3 resale registration dated Oct 03, 2025 covers up to 762,508 existing shares, enabling selling stockholders to resell using various methods. The company is not selling securities under this registration and will not receive proceeds from these resales.
Market Pulse Summary
This announcement highlighted record preliminary FY 2025 revenue of about $31.8–$32.0 million, implying roughly 26% growth from $25.2 million in 2024, and Q4 2025 revenue of $9.0–$9.2 million with about 30% year‑over‑year growth. Total Cash ended 2025 at $11.6 million, down from $13.2 million at September 30, 2025. Earlier guidance in November called for $31.5–$32.5 million, so investors may watch how final results in March 2026, cash trends, and any use of existing registered shares evolve.
AI-generated analysis. Not financial advice.
- Record revenue of approximately
$31.8 -$32.0 million for full-year 2025 and approximately$9.0 -$9.2 million for the three months ended December 31, 2025 - Revenue growth of approximately
26% over full-year 2024 - Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately
$11.6 million as of December 31, 2025
ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today provided select unaudited preliminary financial guidance for the full year and fourth quarter of 2025.
Financial Guidance
Preliminary unaudited financial guidance for the full year and fourth quarter of 2025:
Revenue: The Company anticipates reporting record full year 2025 revenue of approximately
Cash Position: The Company ended 2025 with approximately
The Company intends to provide a detailed operational and financial update during its fourth quarter and full-year 2025 earnings call in March 2026.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about revenue expectations for the full-year and fourth quarter of 2025; cash position as of the year ended 2025, electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; business prospects around its prescription gammaCore and Quell Fibromyalgia devices, health and wellness products, Truvaga, and other new products and markets, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," and other words of similar meaning, derivations of such words and the use of future dates. Preliminary business results and financial position are subject to change, possibly materially, as we complete our Annual Report on Form 10-K for the year ended Dec. 31, 2025. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, Quell Fibromyalgia, TAC-STIM, and Truvaga, electroCore’s results of operations and financial performance, macroeconomic factors including, but not limited to, inflation and currency fluctuations, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What full-year 2025 revenue did electroCore (ECOR) report in the January 20, 2026 update?
How much revenue did electroCore (ECOR) expect for Q4 2025 in its preliminary guidance?
What was electroCore's (ECOR) cash position at December 31, 2025?
When will electroCore (ECOR) provide audited results or a full financial update for 2025?
Does electroCore's (ECOR) January 20, 2026 guidance include audited figures?
